U
Ursula Reichenpfader
Researcher at Linköping University
Publications - 18
Citations - 654
Ursula Reichenpfader is an academic researcher from Linköping University. The author has contributed to research in topics: Major depressive disorder & Medical encyclopedia. The author has an hindex of 8, co-authored 18 publications receiving 576 citations. Previous affiliations of Ursula Reichenpfader include University of North Carolina at Chapel Hill & Danube University Krems.
Papers
More filters
Journal ArticleDOI
Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.
Gerald Gartlehner,Richard A. Hansen,Laura C Morgan,Kylie Thaler,Linda J Lux,Megan Van Noord,Ursula Mager,Patricia Thieda,Bradley N. Gaynes,Tania M Wilkins,Michaela Strobelberger,Stacey W Lloyd,Ursula Reichenpfader,Kathleen N. Lohr +13 more
TL;DR: Current evidence does not warrant recommending a particular second-generation antidepressant on the basis of differences in efficacy, but differences in onset of action and adverse events may be considered when choosing a medication.
Journal ArticleDOI
Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis.
Ursula Reichenpfader,Ursula Reichenpfader,Gerald Gartlehner,Gerald Gartlehner,Laura C Morgan,Amy Greenblatt,Barbara Nussbaumer,Richard A. Hansen,Megan Van Noord,Megan Van Noord,Linda J Lux,Bradley N. Gaynes +11 more
TL;DR: The overall strength of evidence with respect to the findings is rated as low, and clinicians need to be aware of SD as a common adverse event and should discuss patients’ preferences before initiating antidepressant therapy.
Journal ArticleDOI
Leadership in evidence-based practice : a systematic review
TL;DR: This study aims to systematically review published empirical research on leadership as a determinant for the implementation of evidence-based practice (EBP) and to investigate leadership conceptualization and operationalization in this field.
Book
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review
Gerald Gartlehner,Richard A. Hansen,Laura C Morgan,Kylie Thaler,Linda J Lux,Megan Van Noord,Ursula Mager,Bradley N. Gaynes,Patricia Thieda,Michaela Strobelberger,Stacey Lloyd,Ursula Reichenpfader,Kathleen N. Lohr +12 more
TL;DR: In this paper, the benefits and harms of bupropion, citalopram, desvenlafaxine, duloxetine, escitaloprams, fluoxetines, fluvoxamine, mirtazapine, nefazodone, paroxetinedine, sertraline, trazodone and venlaxine were compared for the treatment of depressive disorders.
Journal Article
Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder
Gerald Gartlehner,Richard A. Hansen,Laura C Morgan,Kylie Thaler,Linda J Lux,Megan Van Noord,Ursula Mager,Patricia Thieda,Bradley N. Gaynes,Tania M Wilkins,Michaela Strobelberger,Stacey Lloyd,Ursula Reichenpfader,Kathleen N. Lohr +13 more
TL;DR: In this article, the benefits and harms of second-generation antidepressants for treating major depressive disorder in adults were compared on the basis of 234 studies, and no clinically relevant differences in the two groups were found.